RS
ANIK icon

R Squared’s Anika Therapeutics ANIK Stock Holding History

R Squared’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$396K Sell
27,065
-23,119
-46% -$343K 0.21% 146
2026
Q1 		$728K Buy
50,184
+8,603
+21% +$99.9K 0.4% 51
2025
Q4 		$400K Buy
41,581
+24,375
+142% +$233K 0.19% 167
2025
Q3 		$162K Buy
17,206
+3,661
+27% +$35K 0.07% 408
2025
Q2 		$143K Buy
+13,545
New +$171K 0.08% 325
2025
Q1 		– Sell
-1,620
Closed -$26.7K – 355
2024
Q4 		$26.7K Buy
+1,620
New +$32K 0.03% 754

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

R Squared's ANIK Position: Q2 2026 in Review

R Squared reduced its Anika Therapeutics (ANIK) stake by 46% in Q2 2026, selling an estimated $343K and leaving 27,065 shares worth $396K. The position accounts for 0.21% of the portfolio, ranked #146.

R Squared first reported a position in ANIK in Q4 2024 and has held it in 6 quarters since. The position peaked at $728K in Q1 2026. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • R Squared held 27,065 shares of Anika Therapeutics worth $396K as of Q2 2026.
  • R Squared sold 23,119 Anika Therapeutics shares in Q2 2026, an estimated $343K.
  • Anika Therapeutics made up 0.21% of R Squared's portfolio in Q2 2026, its #146 holding.
  • R Squared first reported a position in Anika Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • R Squared's Anika Therapeutics position peaked at $728K in Q1 2026.
  • 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.